Skip to content
Screener

TG Therapeutics TGTX Q1 2025 earnings

Reported May 5, 2025 · Before market open

Revenue$120.9MMiss by $13.3M
EPS$0.03Miss by $0.15
Revenue estimate$134.2M
EPS estimate$0.18

Next report

Nov 2, 2026 (in a month)
Revenue estimate$245.2M
EPS estimate$0.36

Financials

Q1 2025

Income statement

See full
Revenue$120.9M+90.4%
Gross profit$105.3M+81.5%
Operating income$8.6M+193%
Net income$5.1M+147%
EPS (diluted)$0.03+143%

Balance sheet

See full
Cash & equivalents$132.1M+75.1%
Total debt$253.7M+127%
Total equity$237.3M+48.2%
Total assets$656.7M+75.9%

Cash flow

See full
Operating cash flow-$28.7M-250%
CapEx$25.0K—
Free cash flow-$28.7M-250%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$6.19B+164%
Enterprise value$6.31B+165%
P/E158.2×—
P/S16×+7.9×

Profitability

See full
Gross margin87.4%-6.1pp
Operating margin15.5%—
Net margin10.1%—

Returns & leverage

See full
Return on equity19.7%—
Debt / equity1.1×+0.4×
Current ratio4×+0.4×

FAQ

When did TG Therapeutics report Q1 2025 earnings?
TG Therapeutics (TGTX) reported Q1 2025 earnings on May 5, 2025 before market open.
What were TG Therapeutics's Q1 2025 revenue and EPS?
TG Therapeutics reported revenue of $120.9M and eps of $0.03 for Q1 2025.
Did TG Therapeutics beat estimates in Q1 2025?
Revenue missed the consensus estimate of $134.2M by $13.3M. EPS missed the consensus estimate of $0.18 by $0.15.
How did TG Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 90.4% from $63.5M a year earlier.
Where can I find TG Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001437749-25-014402) and the 10-Q periodic report (0001437749-25-015804) directly on SEC EDGAR. The filing index links above go to sec.gov.